Post in question16 Jan 2020 19:03
Good post from a.n.other forum Anyhow now onto TRX. This company has spent £10’s millions developing their FDA approved portfolio. The market Tissue Regenix operate it is significantly in growth. The ambient stable technology offered by TRX is a huge benefit as it removes the expensive chilled distribution costs relied upon by their competitors. Tissue Regenix is a young company with a CFO now acting as CEO so don’t expect fireworks from their PR team. He is calculated and knows what needs to be done to recover the MCAP to £100m. Now look over the Atlantic. The majority of sales are in the USA along with production. This would make a perfect marriage with one of the major distributors like Medline or McKesson, who are alway looking for new tech companies to buy. I personally hope this doesn’t happen, as within a year I believe the share price will be plus 10p. Finance update should be black and white. MIDCAP will be the ongoing partner short and medium term. They just want TRX to spend their own money before they spend theirs. (RNS could have been worded better). With all focus on America we forget the ROW sales opportunities. Following the positive move to outsource some of the less critical portfolio, this will increase availability and allow the business to open up new markets. Don’t forget we can buy tomorrow thanks to Woodford. That is the only reason. I am making the most of this and will continue to buy and hold. For me this is one of the most exciting companies on AIM. I feel for those who lost money on DEB and more recently LEK. In the world of AIM their are plenty of wasps, but once in a while you find the Queen Bee. Good luck all genuine holders.
Sign In
Follow the stocks
